Scholarlink

<p>Platelets correspond to one of the most abundant components of the blood and shape the tumor microenvironment, modulate antitumor immune responses, and influence clinical outcomes in cancer patients. Recent studies have expanded our understanding of the mechanisms underlying platelet-immune interactions in cancer, including antigen presentation, immune cell activation, and immunosuppressive signaling. Consequently, platelet-based and platelet-targeted therapies have emerged as promising strategies for enhancing antitumor immunity and improving responses to immunotherapy. However, specifically targeting tumor-educated platelets while minimizing adverse effects, particularly bleeding complications, remains a major challenge. In this review, we summarize the current evidence supporting the dual role of platelets in cancer immunity and discuss how engineered platelets may be leveraged to optimize therapeutic outcomes, highlighting their potential clinical applications and the integration of platelet-targeted approaches into next-generation cancer immunotherapies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Platelets as regulators of cancer immunity: mechanisms and therapeutic perspectives

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月5日

查看全文
  • Juscelino Carvalho de Azevedo Junior,
  • Lívia Érika Carlos Marques,
  • Francisco Breno S. Teófilo,
  • Guilherme Cardoso Almada,
  • Fernanda Jardim da Silva,
  • Felipe Mateus Souza Serrão,
  • Vanessa Morais Freitas,
  • Danielle Queiroz Calcagno

摘要

Platelets correspond to one of the most abundant components of the blood and shape the tumor microenvironment, modulate antitumor immune responses, and influence clinical outcomes in cancer patients. Recent studies have expanded our understanding of the mechanisms underlying platelet-immune interactions in cancer, including antigen presentation, immune cell activation, and immunosuppressive signaling. Consequently, platelet-based and platelet-targeted therapies have emerged as promising strategies for enhancing antitumor immunity and improving responses to immunotherapy. However, specifically targeting tumor-educated platelets while minimizing adverse effects, particularly bleeding complications, remains a major challenge. In this review, we summarize the current evidence supporting the dual role of platelets in cancer immunity and discuss how engineered platelets may be leveraged to optimize therapeutic outcomes, highlighting their potential clinical applications and the integration of platelet-targeted approaches into next-generation cancer immunotherapies.